# Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

> **NCT00450944** · PHASE1 · COMPLETED · sponsor: **Albert Einstein College of Medicine** · enrollment: 10 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins

## Key facts

- **NCT ID:** NCT00450944
- **Lead sponsor:** Albert Einstein College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02-22
- **Primary completion:** 2008-10-27
- **Final completion:** 2010-04-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450944, "Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00450944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*